Document is current
Any future updates will be listed below
-
Authors
LaFleur, Martin W.
Miller, Brian C.
Sharpe, Arlene H.
-
License Information
Text and Data Mining valid from 2020-01-01
Version of Record valid from 2020-01-01
-
More Information
Article History
First Online: 7 January 2020
Competing interests
: A.H.S. has patents on the PD-L1/PD-L2/PD-1 pathway and on tumour immunotherapy licensed by Roche, Genentech and Novartis (US patent nos. 7,432,059, 7,722,868, 8,652,465, 9,457,080, 9,683,048, 9,815,898, 9,845,356, 9,988,452, 10,202,454 and 10,370,446), consults for Novartis, serves on the scientific advisory boards for Surface Oncology, SQZ Biotech, Elstar Therapeutics, Elpiscience, Selecta and Monopteros, and has received research funding from Merck, Novartis, Roche, Ipsen, UCB and Quark Ventures. The remaining authors declare no competing interests.
